Stocks › ABBV

AbbVie Inc.

ABBV·NYSE·United States United States·USD
$286.20
+2.66 (+0.94%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
ABBV
AbbVie Inc. · NYSE
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ABBVS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of ABBV by members of U.S. Congress · 339 on record · 19 in the last 12 months
All congressional trades →
PoliticianStockTypeFiledTraded
Ro KhannaRo KhannaHouse · D · CA ABBVAbbVie Inc. · Common Stock Purchase
$15,001 - $50,000
Nov 5, 2026 Oct 7, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA ABBVAbbVie Inc. · Common Stock Sale
$15,001 - $50,000
Oct 8, 2026 Sep 4, 2026 Filing ↗
Pete SessionsPete SessionsHouse · R · TX ABBVAbbVie Inc. · Stock Sale
$15,001 - $50,000
Sep 18, 2026 Sep 14, 2026 Filing ↗
Alan ArmstrongAlan ArmstrongSenate · R · OK ABBVAbbVie Inc. · Stock Purchase
$15,001 - $50,000
Jul 21, 2026 Mar 27, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA ABBVAbbVie Inc. · Stock Purchase
$1,001 - $15,000
Jul 7, 2026 Jun 2, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA ABBVAbbVie Inc. · Common Stock Purchase
$15,001 - $50,000
Jun 10, 2026 May 15, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA ABBVAbbVie Inc. · Stock Purchase
$15,001 - $50,000
Jun 10, 2026 May 1, 2026 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ ABBVAbbVie Inc. · Stock Sale
$1,001 - $15,000
Jun 3, 2026 May 5, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA ABBVAbbVie Inc. · Common Stock Sale
$15,001 - $50,000
May 11, 2026 Apr 13, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA ABBVAbbVie Inc. · Common Stock Sale
$15,001 - $50,000
Apr 7, 2026 Mar 30, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA ABBVAbbVie Inc. · Common Stock Purchase
$15,001 - $50,000
Mar 9, 2026 Feb 5, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA ABBVAbbVie Inc. · Common Stock Purchase
$1,001 - $15,000
Feb 6, 2026 Jan 23, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA ABBVAbbVie Inc. · Common Stock Sale
$15,001 - $50,000
Feb 6, 2026 Jan 29, 2026 Filing ↗
Julie JohnsonJulie JohnsonHouse · D · TX ABBVAbbVie Inc. · Stock Sale
$1,001 - $15,000
Jan 15, 2026 Dec 18, 2025 Filing ↗
Julia LetlowJulia LetlowHouse · R · LA ABBVAbbVie Inc. · Stock Sale
$1,001 - $15,000
Jan 13, 2026 Dec 8, 2025 Filing ↗
Julia LetlowJulia LetlowHouse · R · LA ABBVAbbVie Inc. · Stock Purchase
$1,001 - $15,000
Jan 13, 2026 Oct 23, 2024 Filing ↗
Julia LetlowJulia LetlowHouse · R · LA ABBVAbbVie Inc. · Stock Sale
$1,001 - $15,000
Jan 13, 2026 Jan 24, 2025 Filing ↗
Julia LetlowJulia LetlowHouse · R · LA ABBVAbbVie Inc. · Stock Purchase
$1,001 - $15,000
Jan 13, 2026 Apr 28, 2025 Filing ↗
Julie JohnsonJulie JohnsonHouse · D · TX ABBVAbbVie Inc. · Stock Sale
$1,001 - $15,000
Dec 11, 2025 Nov 13, 2025 Filing ↗
Lisa C. McClainLisa C. McClainHouse · R · MI ABBVAbbVie Inc. · Stock Purchase
$1,001 - $15,000
Nov 21, 2025 Oct 30, 2025 Filing ↗
Lisa C. McClainLisa C. McClainHouse · R · MI ABBVAbbVie Inc. · Stock Sale
$1,001 - $15,000
Nov 21, 2025 Oct 31, 2025 Filing ↗
Lisa C. McClainLisa C. McClainHouse · R · MI ABBVAbbVie Inc. · Stock Sale
$1,001 - $15,000
Nov 21, 2025 Oct 30, 2025 Filing ↗
John BoozmanJohn BoozmanSenate · R · AR ABBVAbbVie Inc. · Stock Sale
$1,001 - $15,000
Sep 12, 2025 Aug 11, 2025 Filing ↗
John BoozmanJohn BoozmanSenate · R · AR ABBVAbbVie Inc. · Stock Sale
$1,001 - $15,000
Sep 12, 2025 Aug 22, 2025 Filing ↗
Julie JohnsonJulie JohnsonHouse · D · TX ABBVAbbVie Inc. · Stock Sale
$1,001 - $15,000
Sep 11, 2025 Aug 14, 2025 Filing ↗

Whale Activity

Position changes in ABBV reported for 2026-09-30 by 4379 institutional filers
Increased: 1796New: 163Held: 514Decreased: 1639Closed: 88No prior filing: 179
  • Increased1796
  • New163
  • Held514
  • Decreased1639
  • Closed88
  • No prior filing179
FilerSharesValueChange
BlackRock, Inc.149.0M$38.97Bdecreased
VANGUARD CAPITAL MANAGEMENT LLC115.7M$30.26Bincreased
STATE STREET CORP82.8M$21.66Bincreased
VANGUARD PORTFOLIO MANAGEMENT LLC49.0M$12.82Bincreased
GEODE CAPITAL MANAGEMENT, LLC47.5M$12.40Bincreased
JPMORGAN CHASE & CO45.3M$11.94Bdecreased
MORGAN STANLEY38.4M$10.04Bdecreased
Capital Research Global Investors31.1M$8.14Bincreased
BANK OF AMERICA CORP /DE/26.4M$6.90Bincreased
FRANKLIN TEMPLETON INC19.7M$5.81Bdecreased
Capital World Investors20.7M$5.40Bincreased
FMR LLC20.2M$5.28Bdecreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by ABBV insiders, by quarter · Form 4
-500.0K-250.0K0250.0K500.0K2025 Q1: -278.9K2025 Q12025 Q2: 02025 Q22025 Q3: -55.7K2025 Q32025 Q4: 02025 Q42026 Q1: -46.3K2026 Q12026 Q2: 02026 Q22026 Q3: -32.7K2026 Q32026 Q4: -40.6K2026 Q4

Recent Insider Transactions

1,573 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICER Sale −40.6K $293.60 $11.9M Nov 9, 2026 Form 4 ↗
Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER Sale −32.7K $250.00 $8.2M Aug 14, 2026 Form 4 ↗
Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER Option exercise +32.7K $79.02 $2.6M Aug 14, 2026 Form 4 ↗
Quaggin Susan EDirector Grant / award +1,118 $0.00 $0 May 8, 2026 Form 4 ↗
Davis Jennifer L.Director Grant / award +1,118 $0.00 $0 May 8, 2026 Form 4 ↗
MEYER MELODY BDirector Grant / award +1,118 $0.00 $0 May 8, 2026 Form 4 ↗
BURNSIDE WILLIAM H.L.Director Grant / award +1,118 $0.00 $0 May 8, 2026 Form 4 ↗
Hart Brett JDirector Grant / award +1,118 $0.00 $0 May 8, 2026 Form 4 ↗
Roberts Rebecca BDirector Grant / award +1,118 $0.00 $0 May 8, 2026 Form 4 ↗
FREYMAN THOMAS CDirector Grant / award +1,118 $0.00 $0 May 8, 2026 Form 4 ↗
WADDELL FREDERICK HDirector Grant / award +1,118 $0.00 $0 May 8, 2026 Form 4 ↗
FALK THOMAS JDirector Grant / award +1,118 $0.00 $0 May 8, 2026 Form 4 ↗
RAPP EDWARD JDirector Grant / award +1,118 $0.00 $0 May 8, 2026 Form 4 ↗
AUSTIN ROXANNE SDirector Grant / award +1,118 $0.00 $0 May 8, 2026 Form 4 ↗
Purdue David RyanSVP, Controller Sale −5,230 $233.56 $1.2M Mar 4, 2026 Form 4 ↗
Siatis Perry CEVP, GC AND SECRETARY Sale −2,600 $235.26 $612K Mar 2, 2026 Form 4 ↗
Siatis Perry CEVP, GC AND SECRETARY Sale −10.3K $234.66 $2.4M Mar 2, 2026 Form 4 ↗
Siatis Perry CEVP, GC AND SECRETARY Sale −5,777 $233.51 $1.3M Mar 2, 2026 Form 4 ↗
Purdue David RyanSVP, Controller Tax withholding Amended −2,108 $232.08 $489K Feb 27, 2026 Form 4 ↗
Crum Demetris DEVP, CHIEF HR OFFICER Tax withholding −1,594 $232.08 $370K Feb 27, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding ABBV · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
56.1M$14.11B0.61%Jun 30, 2026
VANGUARD 500 INDEX FUND
VANGUARD INDEX FUNDS
45.8M$11.52B0.69%Jun 30, 2026
iShares Core S&P 500 ETF
iShares Trust
24.3M$6.12B0.69%Jun 30, 2026
Fidelity 500 Index Fund
Fidelity Concord Street Trust
22.9M$5.88B0.68%Aug 31, 2026
State Street(R) SPDR(R) S&P 500(R) ETF Trust21.4M$5.39B0.69%Jun 30, 2026
VANGUARD VALUE INDEX FUND
VANGUARD INDEX FUNDS
16.8M$4.23B1.66%Jun 30, 2026
State Street(R) Health Care Select Sector SPDR(R) ETF
SELECT SECTOR SPDR TRUST
12.5M$3.14B7.74%Jun 30, 2026
American Mutual Fund11.1M$2.80B2.37%Jul 31, 2026
Capital Income Builder10.1M$2.52B1.93%Jul 31, 2026
VANGUARD DIVIDEND APPRECIATION INDEX FUND
VANGUARD SPECIALIZED FUNDS
10.0M$2.51B1.92%Jul 31, 2026

Mutual funds and ETFs whose N-PORT filings list ABBV's shares (CUSIP 00287Y109), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Vanguard Capital ManagementSCHEDULE 13G · passive (13G) · 132.9M shares7.5%
    Apr 29, 2026 · ↗
  • The Vanguard GroupSCHEDULE 13G/A · passive (13G) · 0 shares0.0%
    Mar 26, 2026 · ↗
  • The Vanguard GroupSCHEDULE 13G/A · passive (13G) · 177.3M shares10.0%
    Jul 7, 2025 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming abbvie as client
$0$2.5M$5.0M$7.5M$10.0M2023 Q1: $1.8M2023 Q2: $990K2023 Q3: $1.2M2023 Q4: $1.3M20232024 Q1: $2.0M2024 Q2: $980K2024 Q3: $1.7M2024 Q4: $1.5M20242025 Q1: $2.6M2025 Q2: $1.7M2025 Q3: $1.6M2025 Q4: $1.9M20252026 Q1: $2.8M2026 Q2: $1.8M2026 Q3: $1.8M2026
  • FEDERAL STREET STRATEGIES, LLCABBVIE, INC. · 2026 Q3 · HCR, MMM$50K
    Filing ↗
  • MARSHALL & POPP, LLCABBVIE INC. · 2026 Q3 · PHA$60K
    Filing ↗
  • WILLIAMS AND JENSEN, PLLCABBVIE, INC. · 2026 Q3 · PHA, DEF, HCR, MMM$90K
    Filing ↗
  • ABBVIE, INC.ABBVIE INC. · 2026 Q3 · CPT, HCR, MMM, TAX$1.1M
    Filing ↗
  • W STRATEGIES, LLCABBVIE INC. · 2026 Q3 · HCR$50K
    Filing ↗

Government Contracts

Federal awards to AbbVie Inc. · USAspending

No federal contract awards found for AbbVie Inc..

U.S. Patents

Recent USPTO applications naming AbbVie Inc.

No USPTO patent applications found for AbbVie Inc..

Annual Financials

From ABBV's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$61.16B$56.33B$54.32B$58.05B$56.20B
Operating income$15.07B$9.14B$12.76B$18.12B$17.92B
Net income$4.23B$4.28B$4.86B$11.84B$11.54B
Diluted EPS$2.36$2.39$2.72$6.63$6.45
Operating cash flow$19.03B$18.81B$22.84B$24.94B$22.78B
Cash and equivalents$5.23B$5.52B$12.81B$9.20B$9.75B
Total assets$133.96B$135.16B$134.71B$138.81B$146.53B
Shareholders' equity-$3.27B$3.33B$10.36B$17.25B$15.41B

As AbbVie Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 20, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in ABBV's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 5.02Officer / director changeNov 2, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsOct 30, 2026
    EDGAR ↗
  • 8-K · Items 5.02Officer / director changeOct 15, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsOct 5, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 9.01Reg FD disclosureSep 3, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsAug 18, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsAug 5, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsJul 31, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsJul 6, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 9.01Reg FD disclosureJun 22, 2026
    EDGAR ↗

About AbbVie Inc.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersNORTH CHICAGO, IL
IncorporatedDE